Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Segment Information and Revenue Recognition (Details)

v3.8.0.1
Summary of Significant Accounting Policies - Segment Information and Revenue Recognition (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2017
USD ($)
segment
Sep. 30, 2016
USD ($)
Number of operating segments | segment 1  
Revenue $ 1,101  
Research Agreement | Multinational Pharmaceutical Company    
Revenue $ 1,100 $ 0